Genmab — Juni 2018
-
Subcutaneous daratumumab show benefit in patients with relapsed or refractory multiple myeloma https://www.youtube.com/watch?v=16TrK-zfVms
-
Lastet they touches upon who the focus lies on during these types of conferences - JNJ or Genmab. It is clearly on JNJ, but this year Genmab was for the first time represented physically (a booth or something I imagine), and the interpretation is that they therefore have a lot of faith in their pipeline.
-
Lastet = lastly. Sorry - I am on the phone.
-
They said that Bluebird presented results which showet 12 months progression free, where the analysis were hoping for 15-18 months.
-
Not sure about the exact definition of progression free. The expert emphadized that CAR-T is not a cure. This was the hope 6 months ago.
-
You are welcome
-
Sorry, but I don’t know.
-
Børsen shows 1 video for free every day. Maybe someone with more knowledge than me can have a look:)
-
Er vi virkelig ved at stabilisere os her under kurs 1000? Virkelig frustrerende fir os sim har et noget højere gak? Er det ikke efterhånden en no brainer i dette niveau? Altså Dara i mm alene burde vel retfærdiggøre en langt højere kurs.
-
Forward p/e jævnfør 4-traders er på 25 for 2019.
Bulder er tilbage på chatten! 
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind